Immunic AG

• 0Reports naming them
• 1Markets in public records
• 0Regions & countries
• 3Active trials they lead^[1]

^[1] ClinicalTrials.gov, Studies led by Immunic AG or a part of it that are recruiting, about to start or running. Retrieved 13 Nov 2026.

Public data

Free public data on Immunic AG

From public registers, not from Acuitas research, with a citation under every number. Each card opens the full list at its source.

About our sources

Company facts

Stock listing

NASDAQ: IMUX

Type

Medicines

Source: SEC EDGAR, Company filings, CIK 1280776. Retrieved 13 Nov 2026.

Clinical trials

3 active studies led by Immunic AG, of 7 in all

Source: ClinicalTrials.gov, Studies with Immunic AG (or a part of it) as lead sponsor; active = recruiting, about to start or running. Retrieved 13 Nov 2026.

See them on ClinicalTrials.gov (opens in a new tab)

SEC filings

Annual reports and other filings with the US Securities and Exchange Commission.

Source: SEC EDGAR, Company filings, CIK 1280776.

Open on SEC EDGAR (opens in a new tab)

Trials over time

Studies Immunic AG leads, by the year they started and their phase

1 2018

1 2019

1 2020

3 2021

1 2022

• Phase 1
• Phase 2
• Phase 3
• Phase 4
• No phase (devices, observational)

Source: ClinicalTrials.gov, Studies with Immunic AG or a part of it as lead sponsor, by start year (since 2015) and phase. Retrieved 13 Nov 2026.

Markets where public records show them

Markets we cover where free public records show Immunic AG: trials they lead, US approvals or WHO prequalification. Each opens the market's report, with the record counts and their sources.

• Multiple Sclerosis Drugs

Search all reports for Immunic AG All companies